ArticleChinese medicine2026
Qinggan Jianpi formula attenuates atherosclerosis by suppressing macrophage lactate transport to activate repair genes via H3K18 lactylation.
Article in Chinese medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Natural Products Modulate Plaque Macrophage Functional Programs in Atherosclerosis.Drug design, development and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundAtherosclerosis (AS) is a complex vascular disease characterized by lipid accumulation, chronic inflammation, and immune dysregulation. Qinggan Jianpi Formula (QGJP), a traditional Chinese medicinal preparation, is widely used for treating lipid metabolism disorders. However, the mechanisms of action and active components remain unclear. These uncertainties restrict its clinical use and necessitate systematic research to clarify them. This study aims to investigate the therapeutic effects of QGJP on AS and to elucidate the role of suppressing macrophage M1 polarization in this process, mediated by the regulation of lactate transport and the promotion of histone lactylation.
methodsIn this study, first, major chemical components of QGJP were identified via UHPLC-HRMS. We employed a high-fat diet (HFD) fed ApoE
resultsQGJP significantly reduced blood lipids, modulated plaque lipid and collagen content, and alleviated aortic pathological damage in AS mice. Moreover, QGJP downregulated the expression of matrix metalloproteinases, adhesion molecules, and chemokines, enhanced endothelial migration capacity, and inhibited monocyte-endothelial adhesion. Further analysis of macrophage polarization phenotypes revealed that QGJP significantly modulated their polarization state. Mechanistically, QGJP suppressed the expression of key glycolytic enzymes while promoting that of FH. Consequently, it reversed the increase in glycolytic activity observed in macrophages during atherosclerosis. Furthermore, QGJP regulated lactate transport by suppressing MCT4 expression. This modulation orchestrated histone H3K18 lactylation, which in turn activated repair-related gene programs in macrophages. Through UHPLC-HRMS analysis, 47 bioactive constituents of QGJP were identified. Experimental validation confirmed that SAA, LA, and CAB effectively inhibited M1 macrophage polarization and activated the expression of proteins related to reparative genes.
conclusionsThis study establishes the critical role of metabolic reprogramming and epigenetic regulation in AS progression. Our findings suggest that a mechanism whereby QGJP alleviates AS may involve the inhibition of the HIF-1α/MCT4 axis and lactate transport, which regulates histone H3K18 lactylation to promote a reparative macrophage phenotype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.